A new acoustic coupling fluid with ability to reduce ultrasound imaging artefacts in brain tumour surgery—a phase I study

Geirmund Unsgård1,2,3 • Lisa Millgård Sagberg2,4 • Sébastien Müller5 • Tormod Selbekk3,5

Received: 10 April 2019 / Accepted: 3 May 2019 / Published online: 18 May 2019
© The Author(s) 2019

Abstract
Background A novel acoustic coupling fluid (ACF), with the potential to reduce surgically induced image artefacts during intraoperative ultrasound imaging in brain tumour surgery, has been evaluated with respect to image quality and safety in a clinical phase 1 study.

Methods Fifteen patients with glioblastoma (WHO grade IV) were included. All adverse events were registered in a 6-month study period. During acquisition of 3D ultrasound image volumes, three different concentrations of the ACF and Ringer’s solution were filled into the resection cavity. The effect of ACF on the ultrasound images was rated by the operating surgeon, and by five independent neurosurgeons evaluating a pair of blinded images from all patients. Images from all patients were analysed by comparing pixel brightness in a noise-affected region and a reference region.

Results The operating surgeon deemed the ACF images to have less noise than images obtained with Ringer’s solution. The blinded evaluations by the independent neurosurgeons were significantly in favour of ACF (p < 0.0001). The analyses of pixel intensities showed that the ACF images had lower amount of noise than images obtained with Ringer’s solution. No radiological sign of inflammation nor circulatory changes was found in the early postoperative MR images. Of the nine complications registered as serious events in the study period, none was deemed to be caused by the ACF.

Conclusion The ultrasound (US) images obtained using ACF have significantly less noise than US images obtained with Ringer’s solution. The rate of adverse events was comparable to what has been reported for similar groups of patients.

Keywords Ultrasound artefacts • Ultrasound image quality • Acoustic coupling fluid (ACF) • Artefact reduction

Introduction
Prognosis in patients with primary brain tumours depends on histological classification where glioblastoma patients have a median survival reported from 9 to 17 months [14, 16]. Tools for enhancing surgical resection of brain tumours, in particular gliomas, are increasing [12, 13, 17, 19]. There seems to be an agreement that achieving extensive resections, when done safely without jeopardising neurological function, is important since it improves survival both for high-grade and low-grade gliomas [6, 12, 15].

Ultrasound is currently used as a tool for providing intraoperative 2D or 3D images for the purpose of tumour localization and resection control. For the use in resection control, the resection cavity is filled with saline or Ringer’s solution to provide acoustic coupling between the ultrasound transducer and tissue. However, attenuation of acoustic waves is very low in water-based irrigation fluids (saline, Ringer’s solution) compared to the brain. This difference in attenuation is the cause of artefacts that may severely degrade the ultrasound images. These artefacts are seen as high-intensity signals at the resection cavity wall and beyond, potentially masking a small tumour remnant and generally make the image interpretation more difficult [11].
The cross-disciplinary research group in the Norwegian National Advisory Unit for Ultrasound and Image-guided Therapy at St. Olav University Hospital, Trondheim, Norway, has developed a fluid (ACF) intended for use in the resection cavity during ultrasound imaging. The purpose of the acoustic fluid is to reduce noise in the ultrasound images, and thereby provide images with better ultrasound image quality, which may provide a better basis for clinical decision making and make it easier to detect small tumour remnants near the end of an operation.

The ACF’s effect on image quality was first tested in laboratory measurements using phantoms or fresh animal cadavers. Safety has previously been assessed through two animal studies [2]. In the first pre-clinical study, we injected the acoustic fluid subcortically in eight rats. The rat brains were harvested 9 days later, and there were normal histopathological findings including immunohistochemistry. In a second preclinical study with six pigs, we injected the fluid in the cerebrospinal fluid circulation. After 13–16 days, tissue sampling of dura and brain parenchyma both above and below the tentorium was performed. Microscopic analysis and immunohistochemistry did not reveal any sign of inflammation or acute cellular response, neither in meninges, nor in brain tissue or vessels. Furthermore, no gliosis nor microglial response was observed. There were no signs of seizure or seizure activity on EEG, and in addition, there were no clinical suspicion of altered neurological function.

A clinical phase I study was thereafter designed, approved and performed to assess safety and efficacy of the new acoustic coupling fluid in surgery of 15 patients with glioblastoma. This paper summarises the results obtained regarding the effect of the fluid on image quality, and the preliminary assessment of patient safety. The main objective of the image analysis was to compare the image quality obtained using three different concentrations of the novel acoustic coupling fluid with the image quality obtained using Ringer’s solution. The patient safety was assessed by clinical variables recorded prior to and during the intervention, as well as in postoperative controls within 24–72 h, 1 month and 6 months.

**Methods and material**

**Study design and objectives**

The clinical study is a single-centre prospective study, performed at the department of Neurosurgery, St. Olav University Hospital, Trondheim, Norway. The study was approved by the regional ethical committee (REC Central, approval 2012/1266) and Norwegian Medicines Agency (EudraCT No. 2012-005567-27). Informed consent was obtained from all individual participants included in the study.

Sponsor of the study was the Norwegian National Advisory Unit for Ultrasound and Image-guided Therapy (USIGT) at St. Olav University Hospital.

The objective of the clinical study was to test the fluid during surgery for histopathologically proven glioblastoma to assess safety and efficacy on image quality. The study was not designed to test the effect on the extent of the resection.

**Study population and baseline characteristics**

The study aimed to include 15 patients, male and female > 18 years undergoing resection for glioblastoma. The exclusion criteria included hypersensitivity to egg protein, peanut protein, soy protein, glycerol and allergies to diary and marine products.

The first patient was included in October 2013, while the last examination of the last patient included in the study was performed on May 3, 2016. A total of 18 patients gave their consent to be included in the clinical study. In three patients, the biopsies taken early in the surgery did not confirm a histopathology of glioblastoma. These three patients were therefore not included in accordance with the study protocol, and the ACF was not used during surgery.

In Table 1 the patient demographics and preoperative status is shown. The patients enrolled in the study had a male domination and a high percentage of tumours located in the left brain hemisphere (73%).

**Fluids and equipment**

The ACF is a sterile mixture consisting of glycerol, vegetable oil, emulsifier and sodium chloride. The testing of the novel ACF involved 3 different dilution of the acoustic attenuating components; ACF-1, ACF-2 and ACF-3. The three different concentrations of ACF was produced by the hospital pharmacy (Sykehusapoteket, St. Olavs Hospital, Trondheim) on the day of surgery.

The ultrasound data were obtained at different stages (two or three) of the surgery, using Ringer’s solution and ACF. The ultrasound acquisition was obtained with the SonoWand Invite system (Sonowand AS, Trondheim, Norway), using a flat linear probe (12 FLA) with frequency range 6–12 MHz. The SonoWand Invite system combines ultrasound imaging with neuronavigation technology, enabling acquisition of 3D ultrasound image volumes during surgery [19]. Navigated intraoperative ultrasound data may be presented as overlays on the preoperative MR data, side-by-side or as 3D US volumes alone. The surgeon is able to navigate seamlessly in 3D US volume. The rapid and flexible image acquisition makes it possible to make repeated ultrasound acquisitions during an operation.
Administration of the fluids

After partial removal of the tumour, the fluids were filled into the resection cavity just prior to ultrasound image acquisition using a 50 ml syringe. After the 3D US acquisitions, the respective fluid was removed using a suction device. The ACF has a white colour. After each ultrasound acquisition with ACF, the fluid was sucked out and the cavity was flushed with Ringer’s solution until there was no discolouration of the Ringer. A laboratory dilution test showed that even by a dilution with water to 0.25% ACF, a considerable discolouration was still observed. Flushing until no discolouration is seen should ensure close to complete removal of ACF after US imaging.

Safety - clinical variables

Safety was assessed by registration of adverse events and by dedicated clinical tests and postoperative MR imaging. Any serious adverse events that occurred throughout the study was reported to the legal authorities (Statens Legemiddelverk) according to ICH/GCP-guidelines.

Research nurses involved in the study were collecting clinical data from the patients, both through clinical examinations and from electronic medical records by using validated outcome measures. In addition, included patients were scheduled for controls as outpatients to both the principal investigator/surgeon (GU) and a research nurse at 1 and 6 months. MRI-images were controlled and assessed by an experienced neuroradiologist. The core patient safety parameters investigated in the study were inflammations of the brain tissue, development of hydrocephalus and epileptic seizures. All detectable adverse events, both during operation as well as events that were registered in the medical journal in the postoperative period, were registered by the research nurses. Serious adverse events (SAEs) and suspected unexpected serious adverse reaction (SUSARs) were reported to the legal authorities (Statens Legemiddelverk).

Clinical variables acquired pre- and postoperatively (1–3 days prior to surgery; 24–72 h, 30 days and 6 months postoperatively) included Karnofsky performance status, Charlson comorbidity index, Glasgow Coma Scale, Mini Mental Status and NIH Stroke Scale. Patient-reported quality of life (EQ-5D 3L) was acquired by self-registration before surgery and telephone controls (at 1 and 6 months). MR T1-weighted images were obtained prior to surgery (1–3 days), early postoperative (24–72 h after surgery), at 1 month and at 6 months. Diffusion-weighted images were acquired early postoperatively in all patients. The postoperative MR images were evaluated with respect to any indications of inflammation in the brain or meningitis, significant circulatory changes or hydrocephalus.

Image evaluation and analyses

The qualitative assessment of the ultrasound images obtained by using the different fluids in the resection cavity was done both in the operating room by the operating surgeon and postoperatively by five independent neurosurgeons.

In the operating room, the ultrasound images acquired using the different fluids in the resection cavity were displayed on the SonoWand system for visual inspection. Each of the
image volumes was individually rated with respect to the degree of image artefacts according to a three-level grading (none – some – much). In addition, the surgeon rated which of the image volumes acquired with the different fluids that provided the overall best image quality with respect to delineation of anatomy and level of noise.

The postoperative assessment of the ultrasound images was performed in a blinded fashion by five consultant neurosurgeons. One image obtained with Ringer’s solution and one image obtained with ACF in the resection cavity was presented in arbitrary order from each patient and rated using a 10-point scale (1 = least, 10 = best). The two images were obtained consecutively with only a few minutes interval. The five observers rated the images by answering the three questions:

1. How easy is it to see the difference between tumour tissue and its surrounding brain tissue in the ultrasound image? (provided that the tumour is not completely resected)
2. How easy is it to interpret the image in the region below the resection cavity in the ultrasound image? (provided a resection cavity is present)
3. How easy is it to use the image to identify remaining tumour tissue (for resection)?

The quantitative image analyses were performed postoperatively by a single operator blinded for the results of the qualitative image analyses using the software 3DSlicer 4.4.0 and Matlab 9.0.0 (MathWorks).

Two different regions of interests (ROI) were selected for analyses in each of the acquired image volumes. One region (30 × 10 × 10 mm) was selected below the resection cavity in the image volume, while the other region (5 × 5 × 5 mm) was selected at similar depth but lateral for the resection cavity and served as a reference region for the expected intensities in the ultrasound image volume as shown in Fig. 1. The operator strived to obtain a reference region in tissue that were expected to be similar as the tissue below the resection cavity, as deemed from the preoperative MR T1 images. That is, if the tissue below the resection cavity was oedematous, the reference region was preferably selected in oedematous tissue and at the same depth, if possible. The median brightness of the pixels in the respectively ROIs was calculated. The fluid providing a median intensity of the ROI #1 being closest to the median intensity of the reference ROI #2, was interpreted to be the fluid providing the most correct representation of tissue in the ultrasound images.

Statistical methods

SPSS Statistics was used for descriptive data analyses. QQ-plots were used to test for normal distribution. Mean ± SD are presented if data is normally distributed while medians and interquartile range (IQR) are presented if data are skewed. Kaplan-Meier was used for survival curve. Independent samples t-test was used for the quantitative image evaluations, comparing the difference in intensity of the two selected ROIs in the images acquired with different fluids in the resection cavity. The Pearson’s chi-squared test was used for evaluation of differences in rating of the images by the surgeon in the operating room.

The postoperative qualitative image evaluation involving five raters and three questions was analysed by using a repeated measures ANOVA (analysis of variance) statistical model.

Results

Ultrasound images with Ringer or ACF in the resection cavity could be successfully obtained from all the included 15 glioblastoma patients and both qualitative and quantitative assessment of the images were performed.

Qualitative assessment of the fluids’ impact on image quality

The ultrasound data acquired with different fluids was displayed on the Sonowand Invite system for qualitative interpretation by the operating surgeon. The 3D image volumes

Fig. 1 Image slice extracted from a 3D US volume, with the two regions of interest (ROIs) selected for analysis of median intensities. The smaller square indicates the reference region (#2), in which similar tissue as below the resection cavity is expected. The larger rectangle (#1) is selected to be directly below the resection cavity, in an area where enhancement artefacts are expected to be present.
were typically displayed as two image slices for each volume as shown in Fig. 2. A navigation pointer was used to inspect the image volumes on the navigation display, with the image slices being extracted on basis of the position and orientation of the navigation pointer.

Intraoperative assessment by the operating neurosurgeon

The operating neurosurgeon (GU) assessed the ultrasound images obtained with Ringer’s solution in the resection cavity to contain more image artefacts than images obtained with any of the variants of ACF. The chi-square test showed a significantly higher noise level in the Ringer images compared to the ACF images \((p < 0.05)\).

The operating surgeons were also asked to choose the image with the best image quality.

The ACF-2 had the highest success rate (# wins), as it was rated to have the best image quality in 19 of 29 test sequences (65.5%). There was no significant difference in the # wins between the three concentrations of ACF. Ringer’s solution had equal quality with the ACF in 1 of 31 test rounds (3.2%).

Postoperative blinded rating by independent neurosurgeons

A pair of images with Ringer’s solution and ACF in random order from each of the 15 operations was evaluated by five independent neurosurgeons. The neurosurgeons were asked to answer three questions for each pair. Table 2 lists the evaluations for all three questions across the 15 image pairs and the five raters. The results were significantly in favour of ACF \((p < 0.0001)\). For question 3, “How easy is it to use the image to identify remaining tumour tissue (for resection)?” the mean difference ACF–Ringer’s was 3.03 (2.39, 3.66). The difference between ACF and Ringer’s solution was significant \((p < 0.00001)\) for all five raters.

As seen in Table 2, there is some heterogeneity in the judgement of image quality (ACF–Ringer) across the 15 images, with no improvement seen in the images from patient 3, and a non-statistically significant difference \((p = 0.10)\) of less than 1 unit seen in the images from patient 10. For the other 13 patients, the differences between ACF and Ringer are all statistically significant, with values ranging between 1.60 and 5.20.

Examples of the ultrasound images that were evaluated for patient 2, 6 and 13 are shown in Figs. 3, 4 and 5.
For the two patients where the neurosurgeons found no difference between ACF and Ringer’s solution the cavities were very narrow, causing the sound waves to mostly go through normal brain tissue as seen in Fig. 6 of patient 3.

**Quantitative image analyses**

The median voxel intensity in a region below the resection cavity (ROI #1) and a reference region (ROI #2) laterally to the resection cavity was calculated for each of the ultrasound image volumes. In Fig. 7, the difference in the median values between ROI #1 and ROI #2 is plotted. The fluid ACF-2 is having the lowest average difference in intensity between the selected regions of interests for the ACF fluids, while Ringer’s solution has the highest average difference. A lower difference indicates an intensity level below the resection cavity being more similar to the intensity level of the reference region, whereas a higher and positive difference in pixel brightness level will indicate an artificial signal enhancement in the region below the resection cavity.

All series of differences ROI #1–ROI #2 for each fluid were normally distributed (Kolmogorov-Smirnov, \( p > 0.2 \)), and consequently \( t \) test (one-sample) was used for the statistical analyses. The statistical analyses show that the images obtained with Ringer’s solution, ACF-1 and ACF-3 have differences significantly greater than zero \( (p < 0.01) \). For images obtained with ACF-2, the null hypothesis of zero difference cannot be rejected \( (p > 0.1) \).

### Table 2 Score of ACF vs. Ringer’s solution for the 15 images (across 5 raters and 3 questions)

| Patient No. | Mean score (SD) Ringer | Mean score (SD) ACF | Difference ACF - Ringer (95% CI) | \( p \) value |
|-------------|------------------------|---------------------|----------------------------------|--------------|
| 1           | 2.80 (1.37)            | 8.00 (0.53)         | 5.20 (4.42, 5.98)                | < 0.0001     |
| 2           | 3.73 (1.71)            | 7.73 (0.70)         | 4.00 (3.02, 4.83)                | < 0.0001     |
| 3           | 3.40 (2.10)            | 3.40 (2.29)         | 0.00 (−1.64, 1.64)               | 1.00         |
| 4           | 2.60 (1.64)            | 7.07 (0.96)         | 4.47 (3.46, 5.47)                | < 0.0001     |
| 5           | 4.87 (1.81)            | 7.33 (0.72)         | 2.47 (1.43, 3.50)                | < 0.0001     |
| 6           | 4.60 (1.59)            | 7.20 (1.74)         | 2.60 (1.35, 3.85)                | 0.0002       |
| 7           | 5.33 (2.32)            | 6.93 (1.28)         | 1.60 (0.20, 3.00)                | 0.0267       |
| 8           | 3.73 (1.94)            | 6.53 (1.92)         | 2.80 (1.35, 4.25)                | 0.0005       |
| 9           | 4.67 (1.88)            | 6.87 (1.13)         | 2.20 (1.04, 3.36)                | 0.0006       |
| 10          | 6.27 (1.71)            | 7.20 (1.26)         | 0.93 (−0.19, 2.06)               | 0.10         |
| 11          | 5.20 (2.08)            | 7.22 (0.82)         | 2.13 (0.96, 3.31)                | 0.0009       |
| 12          | 4.00 (2.07)            | 7.87 (0.92)         | 3.87 (2.67, 5.06)                | < 0.0001     |
| 13          | 4.80 (1.97)            | 7.80 (0.68)         | 3.00 (1.90, 4.10)                | < 0.0001     |
| 14          | 3.20 (2.40)            | 7.20 (1.15)         | 4.00 (2.59, 5.41)                | < 0.0001     |
| 15          | 4.00 (2.04)            | 9.00 (0.85)         | 5.00 (3.83, 6.17)                | < 0.0001     |

Fig. 3 (patient 2). Image a is with Ringer’s solution in the cavity and image b is with ACF. At the tip of the navigation pointer (green dot), there are artefacts in a with the same intensity as remaining tumour tissue, which is absent in b.
Postoperative adverse events and clinical follow-up

The postoperative adverse events were found by inspection of patient journals, discharge reports, MR imaging and interviews with the patients. A few patients refused or were too exhausted to participate in some of the scheduled controls, interviews and/or MRI investigations during the 6-month study period. Accordingly, follow-up data are missing in these patients.

Early postoperative (24–72 h) MR images did not indicate any inflammation or adverse effect in the brain tissue, nor any significant circulatory changes or dilated ventricles in any of the 15 patients included in the study. Neither did the MR examination performed in 13 patients 1 month after the operation indicate any inflammation of tissue or dilated ventricles. In 12 patients having an MR examination at 6 months postoperatively, one of the patients was measured to have dilated ventricles. None of the patients had any indication of inflammation of tissue. Tumour recurrence was found in 5 of 12 patients (42%) at the 6-month follow-up.

In Table 3, there is an overview of the adverse events found by the postoperative controls and by examination of digital patient journals. One patient had fever (38.6 °C) and neck stiffness occurring 6 days after the surgery, along with a CSF leakage causing subcutaneous accumulation. Samples from the subcutaneous CSF were acquired along with samples obtained by lumbar puncture. The CSF samples did not imply any bacterial growth. The CSF of the lumbar samples contained erythrocytes. The CRP was normal.

Two patients were reported to have seizures within 30 days after surgery. One patient had an epileptic seizure...
within 3 days after surgery. This patient had in the 3 weeks before the operation had three episodes with sudden aphasias lasting only a few seconds and three episodes with shivering of right hand lasting about 1 min. The patient was operated in the cingulate gyrus and some tumour tissue was intentionally left behind. The other patient, that was operated in the right sensory cortex and close to right pyramidal tract, had attacks with painful rigidity in the left leg starting 6 days after surgery. It was interpreted as a focal seizure. Antiepileptic drugs had very limited effect. None of the patients were given pre-and postoperative prophylactic antiepileptic drugs. There were two incidences of epidural hematoma, of which one required surgical evacuation.

The median survival for the glioblastoma patients enrolled in the study was 326 days (10.9 months). Figure 8 shows the survival curve. Three of the 15 glioblastoma patients died between the 1-month and the 6-month follow-up period.

**Health-related quality of life (QoL), cognitive function and functional status**

The patients reported their health-related QoL in the EQ-5D questionnaire. A minimal clinically important difference

---

**Fig. 6** (patient 3). Image a is with Ringer’s solution and b is with ACF in the operation cavity. Since the cavity is narrow and the sound waves mostly pass through brain tissue, there is no enhancement artefacts, and the tumour below the cavity is shown in both images.
A MCID of ± 0.15 was used for defining whether the patient's QoL improved or deteriorated [9]. Compared to baseline 5 of 14 patients (36%) had deteriorated at 1 month and 5 of 11 patients (45%) at 6 months after surgery.

Cognitive function of the patients was evaluated using the mini mental status (MMS) and the cognitive functioning scale of EORTC QLQ-C30. For the functioning scale of EORTC QLQ-C30, a MCID of 10 points was used to evaluate improvement or deterioration relative to the status prior to surgery [5]. At 1 month after surgery, 11 patients answered the EORTC QLQ-C30 questionnaire. Four of them reported improved cognitive function (36%), four reported unchanged cognitive function (36%) and three reported deterioration (27%).

For the MMS, a drop of ≥2 compared to the preoperative score was registered in 9 of 14 patients immediately after surgery (24–72 h). At 1 month, three patients had a drop ≥2 compared to the preoperative score.

There was no drop in Glasgow Coma Scale neither immediately after surgery nor after 1 and 6 months. In NIH Stroke

### Table 3 Postoperative events of the included patients

| Type of postoperative event                          | Within 30 days | Between 1 and 6 months |
|------------------------------------------------------|----------------|------------------------|
|                                                      | No. (%)        | No. (%)                |
| Fever (unknown origin)                               | 1 (7)          | 1 (7)                  |
| CSF-leak                                             | 1 (7)          | 0 (0)                  |
| Epileptic seizures                                   | 2 (13)         | 1 (7)                  |
| Epidural hematoma requiring surgery                  | 1 (7)          | 0 (0)                  |
| Epidural hematoma without clinical symptoms          | 1 (7)          | 0 (0)                  |
| UTI/urinary retention                                | 3 (20)         | 0 (0)                  |
| Salmonella infection                                 | 1 (7)          | 0 (0)                  |
| Aloofness (episode of 15 min)                        | 1 (7)          | -                      |
| Subdural effusion                                    | 1 (7)          | 0 (0)                  |
| Pneumonia                                            | 2 (13)         | 1 (7)                  |
| Itchy rash                                           | 2 (13)         | 0 (0)                  |
| Syncope (3 episodes)                                 | 1 (7)          | 0 (0)                  |
| Fungal mouth infection                               | 1 (7)          | 0 (0)                  |
| Cardiac arrhythmia                                   | 0 (0)          | 1 (7)                  |
| Chronic subdural hematoma                            | 0 (0)          | 1 (7)                  |
| Febrile neutropenia                                  | 0 (0)          | 1 (7)                  |
| Death                                                | 0 (0)          | 3 (20)                 |

*Reported as serious adverse events (SAEs) or suspected unexpected serious adverse reaction (SUSARs) according to the ICH/GCP-guidelines

![Fig. 8 Cumulative survival curve for the enrolled glioblastoma patients](image-url)
Scale 3 of 14 patients had a change > 2 immediately after the operation. At 1 month and 6 months after the operation, this change was registered in one patient.

The functional impairment was evaluated by a drop in KPS from ≥ 70 before surgery to ≤ 60 after surgery. Immediately after surgery (24–72 h), such a drop was registered in seven patients. One month after surgery, the number with such a drop compared to preoperative value was reduced to three patients.

### Discussion

The study has investigated the safety and image quality of a novel acoustic coupling fluid (ACF) intended to be used during ultrasound imaging in brain tumour surgery. Three concentrations of ACF were used in addition to Ringer’s solution, which served as the current gold standard.

The image quality for each of the ultrasound images obtained was assessed and rated by the surgeon in the operating room during the ultrasound imaging and in a blinded fashion postoperatively by five neurosurgeons with experience in ultrasound imaging. In addition, the impacts on noise of the three different ACF concentrations and the Ringer’s solution were investigated by quantitative analyses of the pixel brightness in defined ROI’s. All the analyses demonstrate that there is less noise in the group of ultrasound images obtained with ACF in the resection cavity compared to the images obtained with Ringer’s solution. The postoperative assessment of the ultrasound images indicates that the improved image quality will make it easier to identify remaining tumour in the area below the resection cavity. The improved ultrasound image quality with ACF may lead to better clinical decision support for the surgeons.

When considering the improvement in image quality for the individual patients, there was none of the cases where the use of ACF led to poorer image quality compared to Ringer’s solution. However, in two cases with small resection cavities, the postoperative analyses indicated a similar image quality between ACF and Ringer. This is in accordance with the theoretical background for the artefacts. As long as the sound waves go through tissue, there will not be enhancement artefacts. Therefore, the subjective interpretation of the degree of improvement in image quality will also depend on the size of the resection cavity.

When comparing the noise level observed in the three different concentrations of ACF, the differences were small compared to the differences between ACF and Ringer’s solution. The attenuation of the fluid is a balance between being too low (compared to attenuation in brain tissue) and thereby not reducing the noise as much as it could have done and being too high which could lead to shadowing artefacts in the ultrasound image below the resection cavity. For that reason, fluid with three different concentrations of the sound attenuating component was tested. The quantitative analyses of image contrast show that the ACF-2 images are most similar to the intensity of a reference region with similar tissue. The surgeon’s perioperative assessment of the different images acquired with ACF in the cavity also favours the same concentration (ACF-2).

There were three deaths within the 6-month study period. Two of the patients died approx. 5.5 months after surgery, with recurrent tumour apparent on the MRI obtained 1 month after surgery. The deaths were caused by tumour progression. One patient died 5 months after surgery. In this patient, it was not identified tumour recurrence on the 1-month MRI examination. The adjuvant treatment with radiation therapy and chemotherapy was stopped early after it was initiated, due to neutropenia and deteriorated health. Even if MRI has not verified tumour growth for this patient, the death of the patient was considered to be caused by tumour growth and factors related to the progression of the disease. Both overall survival and 6-month death rate for patients in this study are comparable to the results reported for a similar group of patients consecutively operated at the same hospital from 2011 to 2013 [10].

Postoperative MRI examinations have not revealed any signs of inflammations nor toxicity in the brain of the patients included in the study. MRI is known to be sensitive for detection of inflammation in the brain parenchyma [8]. This indicates that the ACF fluid is well tolerated by the brain parenchyma. Nor has it been found any circulatory changes in the early postoperative MR images.

Patient number 1 was suspected to have meningitis 6 days after surgery, with headache, fever and some neck stiffness. The CRP was normal and tests of the cerebrospinal fluid (CSF) did not show any bacterial growth. This patient was operated for a very large tumour that invaded the ventricles. The tumour was radically removed resulting in a large opening from the resection cavity into the ventricles, and some blood had inevitably entered the ventricle system. There was blood in the samples of CSF taken days after surgery. The blood in the ventricle system might therefore explain the fever episode and neck stiffness. It seems less likely that the use of ACF in the earlier stages of surgery before opening of the ventricles should have caused the above stated complication.

In the same patient, the radiologist reported enlarged ventricles as well as tumour growth at the 6-month control. The clinical follow-up did not reveal any clinical symptoms of hydrocephalus. The increased risk for hydrocephalus by entering the ventricle during tumour surgery is well known. For example, a paper from Henry Ford Hospital in Detroit reported 11% hydrocephalus in such patients [3].

Rates of postoperative seizures in patients with gliomas without preoperative seizures vary in the literature from 4 to 40% in the year following resection, with the first
postoperative seizure generally occurring within the first month after craniotomy [7]. In a prospective randomised study of perioperative seizure prophylaxis from MD Anderson Cancer Center in Houston, the authors found new seizures during the 30-day postoperative period in 18.6% of 46 glioma operations (80% were high-grade gliomas) with no benefit of prophylaxis [20]. In a retrospective study of 184 glioblastoma patients, new onset epilepsy during the first 30 days after resection was found in 16% in the group without prophylactic antiepileptic medication [4]. The two patients registered to have postoperative seizures in our study are within the level of what has been reported by others. However, due to the low number of patients in our study and the large variation in postoperative seizures in the literature, we cannot exclude the possibility that ACF can contribute to the generation of new seizures.

One patient reported itchy rash on the first postoperative examination at 1 month. The condition was not treated, and the rash was not reported in the patient’s journal or the nursing log. Another patient had a rash on back/neck 2 days after surgery that was reported as a possible urticaria. Some medication was altered; the patient was given antihistamine (cetirizin) and the rash went away the same day.

**Quality of life, cognitive function and functional status**

The patient reported quality of life with deterioration found in 36% and 45% at 1 month and 6 months respectively after surgery was similar to the values found in a study of comparable patients operated at the same hospital from 2011 to 2013, and assessed in the same way [9].

In the early postoperative examination (24–72 h) of MMS, there was a drop. Postoperative cognitive dysfunction is a well-known entity [18] that to our knowledge has not been studied in the immediate postoperative period after brain surgery. It is likely, however, that the operation itself, and also the certainty of having an incurable tumour, will influence the ability of the patients to answer questions immediately after the operation.

The Karnofsky performance index also dropped immediately after surgery. We did not find results to compare with in the literature, but it is likely that the scoring immediately after a brain tumour operation will be influenced by the operation itself. In a month, the functional activity was regained in most of the patients.

Patients operated for glioblastoma have a high rate of postoperative adverse events [1]. This makes it difficult to identify adverse events related to the intervention. Even though the adverse events in this study are within the limits of what have been reported in other publications, indisputable safety data requires a higher number of patients operated using ACF in ultrasound-guided surgery.

**Conclusion**

In a phase I study of glioblastoma patients, a novel acoustic coupling fluid (ACF) was able to remove artefacts that appear in ultrasound images towards the end of tumour removal. Our findings indicate that the improved ultrasound image quality with ACF may lead to better clinical decision support for the neurosurgeons.

Adverse events or complications detected in this limited group of patients are comparable to what has been reported for similar patients in other publications.

**Acknowledgements** Consultant in radiology PhD Kjell Arne Kvistad for his reviewing of the MR images.

Professor John Norrie (Edinburgh University, Scotland) for his contribution in the statistical evaluation of the postoperative image rating.

The neurosurgeons that has performed the postoperative image rating: Assistant professor Asgeir Jakola (Salgrenska University Hospital), Professor Sasha Gulati (St. Olav University Hospital), consultant neurosurgeon Oddrun Fredriksli (St. Olav University Hospital), consultant neurosurgeon, PhD, Vidar Rao (St. Olav University Hospital), consultant neurosurgeon So Hara (St. Olav University Hospital).

Professor Ole Solheim and assistant professor Asgeir Jakola for their participation in the clinical steering group of the study.

Study nurse Camilla Brattbakk for interviewing patients.

**Funding** No external funding. The study was funded by Norwegian National Advisory Unit for Ultrasound and Image guided therapy, Trondheim, Norway.

**Compliance with ethical standards**

**Informed consent** Informed consent was obtained from all individual participants included in the study.

**Conflict of interest** Two of the authors (GU and TS) have a patent on the ACF. When this study was performed, TS was employed by the research organisation SINTEF, and GU was Head of Neurodivision and Chief of Neurosurgical Department at St Olav University Hospital. TS is now an employee of the start-up company (Sonoclear A/S) that is developing the ACF for commercialization, while GU is a medical advisor.

**Ethical approval** All procedures performed in studies were in accordance with the ethical standards of the institutional and/or national research committee (REC Central, approval 2012/1266) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Drewes C, Sagberg L, Jakola AS, Gulati S, Solheim O (2015) Morbidity after intracranial tumor surgery: sensitivity and specificity of retrospective review of medical records compared with patient-reported outcomes at 30 days. J Neurosurg 123:972–977

2. Jakola AS, Jorgensen A, Selbekk T, Michler RP, Solheim O, Torp SH, Sagberg LM, Aaalahl P, Unsgård G (2014) Animal study assessing safety of an acoustic coupling fluid that holds the potential to avoid surgically induced artifacts in 3D ultrasound guided operations. BMC Med Imaging 14:11. https://doi.org/10.1186/1471-2342-14-11

3. John JK, Robin AM, Pabane AH, Rammo RA, Schultz LR, Sadry NS, Lee IY (2017) Complications of ventricular entry during craniotomy for brain tumor resection. Neurosurgery 127:426–432

4. Liang S, Zhang J, Zhang S, Fu X (2016) Epilepsy in adults with supratentorial glioblastoma: incidence and influence factors and prophylaxis in 184 patients. PLoS One 11:e0158206. https://doi.org/10.1371/journal.pone.0158206

5. Mamingwa J, Quinten C, King M, Ringash J, Osoba D, Coens C et al (2011) Minimal clinically meaningful differences for the EORTC QLQ-C30 and EORTC QLQ-BN20 scales in brain cancer patients. Ann Oncol 22:2107–2112

6. McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K, Burger PC et al (2008) Extent of surgical resection is not associated with survival in patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 63:700–707. https://doi.org/10.1227/01.neu.00000325729.41085.73

7. Neal A, Kwan P, Moroff O, A’O’Brien TJ (2017) Post-operative seizure prophylaxis in gliomas. Transl Cancer Res 6(supplement 6):475–489

8. Quarantelli M (2015) MRI/MRS in neuroinflammation: methodological aspects of current practice. J Neurosurg 28:E7. https://doi.org/10.1017/S1470-2045(09)00097-5

9. Sagberg LM, Jakola A, Solheim O (2014) Quality of life assessed with EQ-5D in patients undergoing glioma surgery: what is the responsiveness and minimal clinically important difference? Qual Life Res 23:1427–1434. https://doi.org/10.1007/s11136-013-0993-4

10. Sagberg LM, Solheim O, Jakola AS (2016) Quality of survival the first year with glioblastoma: a longitudinal study of patient-reported quality of life. J Neurosurg 124(4):989–997. https://doi.org/10.3171/2015.4.JNS15194

11. Selbekk T, Jakola A, Solheim O, Johansen TF, Lindseth F, Reinertsen I, Unsgård G (2013) Ultrasound imaging in neurosurgery: approaches to minimize surgically induced artefacts for improved resection control. Acta Neurochir 155(6):973–980. https://doi.org/10.1007/s00701-013-1647-7

12. Senft C, Bink A, Franz K, Vatter H, Gasser T, Seifert V (2011) Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial. Lancet Oncol 12:997–1003. https://doi.org/10.1016/S1470-2045(11)70196-6

13. Stummer W, Pichlmueier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ, Group AL-GS (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401. https://doi.org/10.1016/S1470-2045(06)70665-9

14. Stummer W, Reulen HJ, Meinel T, Pichlmüier U, Schumacher W, Tonn JC, Rohde V, Oppel F, Turovski B, Wociejewodsky C, Franz K, Pietsch T, Group AL-GS (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62:564–576; discussion 564-576. https://doi.org/10.1227/01.neu.0000317304.31579.17

15. Stummer W, Tonn JC, Mehndorff HM, Nestler U, Franz K, Goetz C, Bink A, Pichlmueier U, Group AL-GS (2011) Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. Clinical article. J Neurosurg 114:613–623. https://doi.org/10.3171/2010.3.JNS097

16. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgiear A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330

17. Szelényi A, Bello L, Duflau F, Hava E, Feigl GC, Galanda M, Neuloh G, Signorelli F, Sala F, Workgroup for Intraoperative Management in Low-Grade Glioma Surgery within the European Low-Grade Glioma N (2010) Intraoperative electrical stimulation in awake craniotomy: methodological aspects of current practice. J Neurosurg 28:E7. https://doi.org/10.1017/S1470-2045(09)00097-5

18. Tsai TL, Sands LP, Leung JM (2010) An update on postoperative cognitive dysfunction. Adv Anesth 28:269–284

19. Unsgård G, Rygh O, Selbekk T, Muller TB, Kolstad F, Lindseth F, Hermes TA (2006) Intra-operative 3D ultrasound in neurosurgery. Acta Neurochir 148:235–253. https://doi.org/10.1007/s00701-005-0688-y

20. Wu AS, Trinh VT, Suki D, Graham S, Forman A, Weinberg JS, McCutcheon IE, Prabhoo SS, Heimberger AB, Sawaya R, Wang X, Qiao W, Hess K, Lang FF (2013) A prospective randomized trial of peri-operative seizure prophylaxis in patients with intraparenchymal brain tumours. J Neurosurg 118:873–883

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Comments Intraoperative ultrasound has been used in neurosurgical procedures for over 40 years now. Improved image quality of modern ultrasound machines in combination with their integration in navigational setups allowing to acquire 3-dimensional ultrasound and to display ultrasound along preoperative image datasets facilitating image interpretation has resulted in a renaissance of intraoperative ultrasound usage in tumour resections. Despite these technical advances, still image artefacts hinder reliable ultrasound image evaluation. Among these artefacts, a major challenge is high intensity signal artefacts at the wall of a resection cavity that impede to judge resection completeness especially in glioma resections. Unsgård et al. present a phase I study investigating the application of an acoustic coupling fluid, which seems to greatly reduce these artefacts at the wall of a resection cavity which will lead to more complete resections, which will have to be proven in upcoming studies.